By Nancy Lapid (Reuters) -GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health ...

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

Jeremy Siegel, professor emeritus of finance at the University of Pennsylvania’s Wharton School of Business and Wisdom Tree chief economist, appeared on CNBC’s ‘Squawk Box’ to ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Vishwanath Swarup as Commercial Head - ...

The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...